Preferred Label : Natalizumab;

MeSH definition : A humanized monoclonal immunoglobulin G4 antibody to human INTEGRIN ALPHA4 that binds to the alpha4 subunit of INTEGRIN ALPHA4BETA1 and integrin alpha4beta7. It is used as an IMMUNOLOGIC FACTOR in the treatment of RELAPSING-REMITTING MULTIPLE SCLEROSIS and CROHN'S DISEASE.;

MeSH hyponym : antegren; tysabri;

Wikipedia link : https://en.wikipedia.org/wiki/Natalizumab;

Is substance : O;

Details


Main resources

You can consult :

A humanized monoclonal immunoglobulin G4 antibody to human INTEGRIN ALPHA4 that binds to the alpha4 subunit of INTEGRIN ALPHA4BETA1 and integrin alpha4beta7. It is used as an IMMUNOLOGIC FACTOR in the treatment of RELAPSING-REMITTING MULTIPLE SCLEROSIS and CROHN'S DISEASE.

https://ansm.sante.fr/tableau-marr/natalizumab-1
2024
false
false
false
France
French
Natalizumab
risk management
Natalizumab
natalizumab
guidelines for drug use
patient education handout
continuity of patient care
Drug-Related side effects and adverse reactions
opportunistic infections
leukoencephalopathy, progressive multifocal
immunologic factors
immunologic factors
multiple sclerosis

---
https://www.ema.europa.eu/en/medicines/human/EPAR/tyruko
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Natalizumab
Natalizumab
natalizumab
biosimilar pharmaceuticals
multiple sclerosis
drug approval
europe
infusions, intravenous
immunologic factors
immunologic factors
drug interactions
pregnancy
breast feeding
continuity of patient care
drug evaluation, preclinical
adult
integrin alpha4beta1

---
https://ansm.sante.fr/tableau-marr/natalizumab
2022
false
false
false
France
French
guidelines for drug use
patient education handout
Natalizumab
injections, subcutaneous
infusions, intravenous
risk management
Natalizumab
leukoencephalopathy, progressive multifocal
multiple sclerosis
continuity of patient care
risk assessment
natalizumab

---
https://www.has-sante.fr/jcms/p_3287332/fr/tysabri-150-mg-natalizumab
2021
false
false
false
France
insurance, health, reimbursement
Natalizumab
multiple sclerosis, relapsing-remitting
evaluation of the transparency committee

---
https://www.has-sante.fr/portail/jcms/c_2877334/fr/tysabri
2018
false
false
false
France
multiple sclerosis, relapsing-remitting
treatment outcome
natalizumab
evaluation of the transparency committee
tysabri
Natalizumab
Natalizumab

---
https://www.has-sante.fr/portail/jcms/c_2780899/fr/tysabri
2017
false
false
false
France
French
evaluation of the transparency committee
tysabri
Natalizumab

---
Summary Safety Review - TYSABRI (natalizumab) - Assessing the Potential Risk of Hemolytic Anemia
https://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/tysabri-fra.php
2016
false
false
false
Canada
French
English
drug evaluation
risk assessment
canada
anemia, hemolytic
Natalizumab
natalizumab
multiple sclerosis, relapsing-remitting
infusions, intravenous

---
http://www.has-sante.fr/portail/jcms/c_1234483/tysabri
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-04/tysabri_29022012_avis_ct_11948.pdf
http://www.has-sante.fr/portail/jcms/c_490369/tysabri
2012
false
France
French
Natalizumab
Natalizumab
natalizumab
risk assessment
multiple sclerosis, relapsing-remitting
adult
infusions, intravenous
prenatal exposure delayed effects
opportunistic infections
treatment outcome
follow-up studies
evaluation of the transparency committee

---
https://www.ema.europa.eu/medicines/human/EPAR/Tysabri
2012
false
United Kingdom
English
French
syndication feed
Natalizumab
Natalizumab
drug evaluation
immunosuppressive agents
treatment outcome
natalizumab
immunosuppressive agents
drug evaluation
summary of product characteristics
package leaflet
multiple sclerosis, relapsing-remitting
adult
aged
pregnancy
breast feeding
drug approval
europe

---
https://ansm.sante.fr/uploads/2021/03/11/cc146aa6461948a2fc03ad5e8a08e863.pdf
2011
false
France
French
guidelines for drug use
patient education handout
Natalizumab
Natalizumab
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
multiple sclerosis, relapsing-remitting
natalizumab
infusions, intravenous
adult
integrin alpha4
leukoencephalopathy, progressive multifocal
continuity of patient care
drug monitoring

---
https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2010/14090a-fra.php
https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2010/14629a-fra.php
2010
false
Canada
English
French
Natalizumab
Natalizumab
natalizumab
leukoencephalopathy, progressive multifocal
multiple sclerosis
continuity of patient care
pharmacovigilance note

---
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2008/14527a-fra.php
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2009/14583a-fra.php
2009
false
Canada
French
English
Natalizumab
leukoencephalopathy, progressive multifocal
product surveillance, postmarketing
multiple sclerosis
pharmacovigilance note

---
https://www.cadth.ca/sites/default/files/cdr/complete/cdr_Tysabri_CEDAC%20Recommendation_fr_final.pdf
https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Tysabri_Resubmission_February-25-2009-fr.pdf
2009
false
Canada
French
Natalizumab
multiple sclerosis, relapsing-remitting
natalizumab
drug evaluation

---
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2008/14040a-fra.php
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2008/14527a-fra.php
2008
false
Canada
French
English
Natalizumab
drug hypersensitivity
liver diseases
liver
hyperbilirubinemia
transaminases
pharmacovigilance note

---
Nous contacter.
06/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.